Regeneron Pharmaceuticals About
Regeneron Pharmaceuticals Regeneron is a biopharmaceutical company
that discovers, develops, and intends to commercialize therapeutic medicines for
the treatment of serious medical conditions. Regeneron has therapeutic candidates
in clinical trials for the potential treatment of
obesity, rheumatoid
arthritis, and cancer.
The Company also has preclinical programs in asthma,
allergies, and other diseases and disorders. Regeneron has several investigational product
candidates progressing through all stages of human clinical trials, for a diverse
set of serious diseases, including obesity, rheumatoid
arthritis, and cancer.
AXOKINE® IL-1 --for the potential treatment of obesity
VEGF Trap -- Research has shown that a protein found in the bloodstream
(vascular endothelial growth factor, or VEGF), is secreted by many tumors to stimulate
new blood vessels to grow and support the tumor. When VEGF binds to a protein
its protein receptor, which resides on the surface of blood vessel cells, it stimulates
their growth. In preclinical studies, the VEGF Trap literally “traps” the VEGF
being made by the tumor, stopping it from stimulating the VEGF receptor, and thus
preventing the tumor from promoting blood vessel growth. IL-4/13 Trap
--Evidence from different
laboratories suggests that overproduction of two functionally related
cytokines, Interleukin-4 (IL-4) and Interleukin-13 (IL-13),can initiate an immune
response that can lead to allergy and asthma. The "IL-4/13 Trap" tightly
binds both IL-4 and IL-13 and, in preclinical studies, blocks their actions. IL-1
Trap - - tightly binds IL-1 and potently blocks its effects. In preclinical
studies, the IL-1 Trap decreased inflammation and blocked cartilage erosion
in the joint. More About Regeneron